90564-27-5

Upstream product

• 89942-77-8 methyl 3-hydroxy-2-nitrobenzoate 
• 602-00-6 3-hydroxy-2-nitrobenzoic acid 
• 75-03-6 ethyl iodide 

Downstream Products

• 1639946-92-1 C₉H₈ClNO₄ 
• 1621457-75-7 2-acetylphenyl 3-ethoxy-2-nitrobenzoate 
• 1621457-78-0 1-(3-ethoxy-2-nitrophenyl)-3-(2-hydroxyphenyl)propane-1,3-dione 
• 1621457-81-5 2-(3-ethoxy-2-nitrophenyl)chromone 
• 1621457-84-8 2-(2-amino-3-ethoxyphenyl)chromone 
• 1015689-38-9 2-amino-3-ethoxybenzoic acid 

Relevant academic research and scientific papers

PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

IMINO SULFANONE INHIBITORS OF ENPP1

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine- based inhibitors of ENPP1 of Formula (I) and methods of their use for treating disease mediated by ENPP1.

A chiral oxazoline for catalytic enantioselective Nozaki-Hiyama-Kishi allylation and vinylation of aldehydes

Asymmetric allylation and vinylation of aldehydes with allyl halides and vinyl halides have been achieved using the chromium(II)-oxazoline catalyst. The catalyst promotes the highly efficient enantioselective Nozaki–Hiyama-Kishi (NHK) allylation of aldehydes using allyl bromide, producing the corresponding homoallylic alcohols in good yields (up to 84%) and a high level of enantioselectivity (up to 98% ee). Meanwhile, the NHK vinylation of aldehydes produce desired allylic alcohols in satisfactory yields (up to 88%) and a high level of enantioselectivity (up to 97% ee). We developed a reliable and milder protocol for preparing chiral homoallylic and allylic alcohols.

Towards the development of chromone-based MEK1/2 modulators

Inhibition or allosteric modulation of mitogen-activated protein kinase kinases MEK1 and MEK2 (MEK1/2) represent a promising strategy for the discovery of new specific anticancer agents. In this paper, structure-based design, beginning from the lead compound PD98059, was used to study potential structural modifications on the chromone structure in order to obtain highly potent derivatives that target the allosteric pocket in MEK1. Subsequently, a small series of PD98059 analogs were synthesized to provide a first generation of chromone-based derivatives that inhibit the activation of MEK1 with IC 50 values as low as 30 nM in vitro. Complementary cellular studies also showed that two of the compounds in the series inhibit the activity of MEK1/2 with IC50 values in the nanomolar range (73-97 nM). In addition, compounds in this series were found to inhibit the proliferation of a small panel of human cancer cell lines.